Viewing Study NCT00043355



Ignite Creation Date: 2024-05-05 @ 11:28 AM
Last Modification Date: 2024-10-26 @ 9:07 AM
Study NCT ID: NCT00043355
Status: TERMINATED
Last Update Posted: 2007-11-01
First Post: 2002-08-07

Brief Title: Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection
Sponsor: InterMune
Organization: InterMune

Study Overview

Official Title: A Randomized Double-Blind Placebo-Controlled Phase II Study of Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterials in Previously Treated or Mod-to-Sev Pulmonary Mycobacterium Avium Complex Infection
Status: TERMINATED
Status Verified Date: 2007-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Futility
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this research study is to test the safety and effectiveness of inhaled Interferon gamma-1b IFN-g 1b when administered for 48 weeks and in combination with oral antibiotics which may be administered for up to 72 weeks for the treatment of a lung infection caused by a bacterium called Mycobacterium avium complex

FDA has not approved Interferon gamma-1b for use in patients with MAC infection of the lungs which is the purpose of this studyInterferon gamma-1b and similar proteins play important roles in establishing and maintaining protective immune responses against a variety of microorganisms
Detailed Description: Laboratory research has shown that a mouse form of interferon gamma is effective in treating mice with infections caused by bacteria similar to MAC as well as MAC infection

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None